

Association between Serum Ferritin and Insulin Resistance Markers with Distinct Glycemic Profiles in an Adult Bangladeshi Population

Jhilky MTA¹, Khan EH², Parvin S³, Mia MM⁴, Jahan I⁵, Akter S⁶

ABSTRACT

Background: Type 2 diabetes mellitus (T2DM) is a global health concern. Around 56% of subjects in Bangladesh go undiagnosed, increasing the risk of stroke and cardiovascular issues. Iron stores impact on diabetes is gaining attention, with ferritin as a key biomarker. Hyperferritinemia probably contributes to insulin resistance and subsequently to decreased insulin secretion, causing the development of insulin resistance. The link between ferritin and insulin resistance (IR) varies based on ethnicity, gender, and glycemic state.

Objectives: This study investigates serum ferritin levels in different glycemic stages and explores potential correlations between ferritin and insulin resistance markers (blood glucose, serum insulin and HOMA-IR)

Methods: The study was conducted at the Department of Biochemistry, Sir Salimullah Medical College, Dhaka, Bangladesh, from March 2018 to February 2019. A total of 140 subjects were included to conduct this study. Participants were categorized into three groups: those with normal fasting glucose (NFG group), impaired fasting glucose (IFG group), and newly diagnosed type 2 diabetes mellitus (Diabetic group) according to WHO (2006) criteria. A purposive convenient sampling method was used, focusing on adults aged 25 to 55 years. Exclusion criteria were applied to eliminate individuals with inflammatory diseases, chronic conditions, major cardiovascular events, anemia, or specific medications that could affect ferritin levels.

Results: The study found that serum ferritin levels significantly differed among three glycemic groups (NFG, IFG, and T2DM) with higher levels in T2DM. IFG and T2DM groups also had elevated serum insulin and HOMA-IR. Serum ferritin correlated strongly with fasting blood glucose, serum insulin, HOMA-IR, and BMI. The highest tertile of ferritin levels were associated with IFG & diabetic group.

Conclusion. Elevated serum ferritin levels in IFG and type 2 diabetes may significantly impact on glucose regulation. Compared to NFG, there are high insulin resistance markers (fasting insulin, glucose, HOMA-IR) in T2DM and IFG. They have crucial implications for both therapy and prognosis in these conditions.

Keywords: S.Ferritin, IR Markers, Glycemic state.

Mugda Med Coll J. 2023; 6(2): 57-63

1. Dr. Most. Tasnim Ara Jhilky, Lecturer, Department of Biochemistry, Mugda Medical College, Dhaka-1214.
2. Prof. Ehsanul Haque Khan, Professor and Head, Department of Physical Medicine & Vice-Principal, Mugda Medical College, Dhaka-1214.
3. Prof. Shamima Parvin, Ex-Professor and Head, Department of Biochemistry, Mugda Medical College, Dhaka-1214.
4. Dr. Mohammad Mohsin Mia, Medical Officer, National Institute of Traumatology & Orthopaedic Rehabilitation (NITOR), Dhaka-1207.
5. Dr. Israt Jahan, Lecturer, Department of Biochemistry, Mugda Medical College, Dhaka-1214.
6. Dr. Shahanaz Akter, Lecturer, Department of Biochemistry, Mugda Medical College, Dhaka-1214.

Address of correspondence: Dr. Most. Tasnim Ara Jhilky, Lecturer, Department of Biochemistry, Mugda Medical College, Dhaka. Mobile: +8801716004194; Email: drtasnimrpmc@gmail.com

INTRODUCTION

As a predominant public and medical issue, the emergence of T2DM has increased dramatically in recent years and put a tremendous burden on medical, economic and social infrastructure. The International Diabetes Federation (IDF) estimates that in 2015, there were 415 million people with diabetes worldwide and indicates that the absolute number will reach 642 million by 2040¹. For every diagnosed diabetic case, another one is undiagnosed; overall, undetected people are at significantly higher risk for stroke, coronary artery disease, and peripheral vascular disease. The proportion of undiagnosed DM

in Bangladesh is about 56.0 %¹. While obesity and diabetes are reaching epidemic proportions in the developed world, the role of insulin resistance and its sequelae is gaining prominence². Genetic and environmental factors cause IR & lead to impaired glucose tolerance, and play a crucial pathophysiological role in the development of diabetes³. Insulin resistance occurs before the development of T2DM and might be the best indicator for it⁴. Recent studies have shown Insulin resistance syndrome (IRS) correlated with increased serum ferritin, suggesting the pathophysiological link between the severity of IRS and serum ferritin levels⁵.

There is an increasing interest in the adverse health outcomes associated with elevated body iron stores⁶. Through its oxidative properties, iron has also been suggested to play a role in IR and beta cell dysfunction, which are cardinal features of altered glucose homeostasis⁷ Iron is the body's most abundant metal and an essential human nutrient. It is a cofactor for several enzymes involved in oxidation-reduction reactions due to its ability to exist in two ionic forms-ferrous and ferric⁸. Elevated iron stores may induce diabetes through various mechanisms, including oxidative damage to pancreatic beta cells, impairment of hepatic insulin extraction by the liver and interference with insulin's ability to suppress hepatic glucose production. Long-term microvascular and macrovascular complications of diabetes may be due to raised serum ferritin⁹⁻¹¹. Body iron stores are commonly assessed by serum ferritin, a widely available clinical biomarker to evaluate iron status^{8,12}. Cross-sectional studies indicate an independent link between high iron stores and T2DM occurrence^{13,14}. And found Ferritin, a reliable marker, has been linked to glycemic status and complications of Diabetes Mellitus, including Retinopathy, Nephropathy, Neuropathy, and Vascular dysfunction¹⁵.

A few studies have demonstrated an association between markers of insulin resistance (fasting insulin, glucose and HOMA-IR) and ferritin^{16,17}. They found that plasma ferritin concentrations positively correlate with fasting insulin and fasting glucose. Some observational studies have shown that elevated serum ferritin is associated with IR when assessed by HOMA-IR^{18,19}. Another survey by Suarez-Ortega¹⁹ showed that serum ferritin did not significantly predict HOMA-IR in the healthy Colombian population. A study on the Finnish population

suggests that the strength and direction of the association between serum ferritin and HOMA-IR depend on the population's glycemic state⁷.

In diabetes mellitus, increased glycation of transferrin decreases its ability to bind ferrous iron. Hence, there is an increased pool of free iron, which stimulates increased ferritin synthesis²⁰. An increase in Ferritin synthesis is believed to result in the internalization of Insulin receptors, which contributes to Insulin resistance¹¹. Thus, glucose metabolism is found to be interlinked with iron metabolism and measuring serum ferritin levels as part of diabetic management could aid in predicting the outcomes. Higher ferritin concentrations are observed in Asian populations, and even moderately increased iron stores are associated with diabetes^{12,21}

A previous study observed positive correlation between serum ferritin concentration and HbA1c in T2DM patients in our country²² But association of body iron stores and glucose homeostasis at different glycemic states were unclear.

Hence, We proposed this study to assess the association of serum ferritin to insulin resistance markers (fasting insulin, glucose and HOMA-IR) in three different glycemic states and tried to establish its role in glucose homeostasis.

METHODS

It was a cross-sectional, observational study conducted at the Department of Biochemistry of Sir Salimullah Medical College, Dhaka, Bangladesh, between March 2018 and February 2019. A total of 140 subjects were included to conduct this study divided into three groups: Group A having individuals with normal fasting glucose (NFG group) and Group B having individuals with impaired fasting glucose (IFG group), and Group C having individuals with newly diagnosed type 2 diabetes mellitus (Diabetic group). Adult people aged 25 to 55 years were included. Participants with acute or chronic inflammatory diseases, chronic liver diseases, major cardiovascular events, chronic alcoholism, and anaemia were excluded by history taking and clinical examinations. Conditions that altered ferritin level, e.g. Hemochromatosis, history of blood transfusion or iron therapy in the previous year and subjects with very high serum ferritin level (>800 ng/ml) were excluded. History of taking antidiabetic, lipid-lowering agents, or other medication that affect

carbohydrate, lipid or insulin metabolism were also excluded. Those with malignancy and pregnancy were excluded. All surveys were conducted after obtaining written informed consent. Anthropometric variables were measured accordingly, and a blood sample was collected to measure biochemical variables.

Subjects were selected from the outpatient department (OPD) of Medicine and Endocrinology of Sir Salimullah Medical College and Mitford Hospital, Dhaka, and National Academy for Educational Management (NAEM), Dhaka, as a part of their routine examination. Before collecting specimens, each eligible person was firmly approached and proper counselling about aims, objectives, and risks, benefit and procedure of the study were done. Only voluntary candidates were recruited as participants. Then they were interviewed, and relevant information was recorded systematically in a pre-designed standard datasheet, including general information and history of chronic diseases, and family history of diabetes. Data were checked and edited. All surveys were conducted after obtaining written informed consent. Anthropometric variables were measured accordingly, and a blood sample was collected to measure biochemical variables.

Diabetes was defined according to the WHO 2006 guidelines as having fasting blood glucose measurement ≥ 7.0 mmol/L. Normal fasting glucose (NFG) indicates a healthy state where the blood glucose level is below 6.1 (mmol/L) after fasting. In impaired fasting glucose (IFG) signifies a condition in which the fasting plasma glucose falls between 6.1 and 6.9 mmol/L, suggesting a potential risk for diabetes, or having been diagnosed by a physician. Markers of insulin resistance as assessed by Fasting insulin, glucose and HOMA-IR²³. BMI was calculated as weight in kilograms divided by the square of height in meters.

All statistical analyses were performed using SPSS (statistical package for social science) for Windows 22.0 version. The mean with standard deviation was determined to compare continuous variables. ANOVA test was done to compare continuous variables. Bonferonni test was performed for the comparison of groups. Serum ferritin concentrations were divided into tertiles to observe the trend of the related variables. The statistical significance, direction and strength of linear correlation between two quantitative variables were measured using

Pearson's correlation coefficient test. $p < 0.05$ was considered a test of significance in all statistical tests. Sample size was determined by applying the formula for a comparison of two means. Using IR values from Kim et al.²⁴

The study was approved by the Ethical Review Committee of Sir Salimullah Medical College, Dhaka, Bangladesh.

RESULTS

The study is basically targeted to analyze the serum ferritin behaviour in the three groups representing different stages of glycemia. Table-I meticulously compiles mean values and standard deviations (SD) of baseline and biochemical parameters across three distinct glycemic groups. Notably, parameters such as age, BMI, SBP, DBP, WC, WHR, fasting plasma glucose, serum insulin, HOMA-IR, and serum ferritin exhibited significant differences among these groups ($p < 0.001$), as validated by the ANOVA test.

Upon applying the Bonferroni test for intergroup comparisons, it emerged that serum ferritin levels were notably higher ($p < 0.001$) in individuals with Type 2 Diabetes (T2DM) compared to those in the Impaired Fasting Glucose (IFG) group. Furthermore, subjects with IFG and T2DM displayed significantly elevated ($p < 0.001$) serum insulin and HOMA-IR levels compared to the Normal Fasting Glucose (NFG) group. Specifically, the mean ferritin concentration was markedly higher in subjects with IFG (84.04 ± 80.79) and newly diagnosed T2DM (158.1 ± 44.9) in comparison to those with NFG (40.50 ± 28.512) (Fig. 1).

Table-II shows insightful correlations between serum ferritin and key variables – fasting blood glucose, serum insulin, HOMA-IR – across the studied groups. Notably, strong correlations existed between serum ferritin and fasting blood glucose, serum insulin, and HOMA-IR levels. Furthermore, a significant correlation was found between serum ferritin and participants' Body Mass Index (BMI). These correlations were consistent across groups, lacking significant differences. The normal reference interval of serum ferritin has a wide range because of age and gender variations⁹ The reference range for adult male is between 20-270 $\mu\text{g/L}$ and that of adult female is 10-120 $\mu\text{g/L}$. In the current study, we also observed that ferritin distribution was positively skewed. Higher tertiles of serum ferritin were notably ($\hat{A}0.01$) associated with Type 2 Diabetes (T2DM) Illustrated in Figure 2.

Table-I: Characteristics of the studied population (n=140)

Variables	Group A (NFG) (n=60)	Group B (IFG) (n=50)	Group C (T2DM) (n=30)	p-value	
Age (years)	35.60±8.77	42.64±8.54	49.73±5.13	<0.001	
BMI (kg/m ²)	23.25±2.18	27.74±2.29	27.75±2.29	<0.001	
SBP (mmHg)	113.88±10.65	115.20±7.57	118.9±10.7	<0.001	
DBP (mmHg)	75.50±8.61	83.60±5.69	87.7±4.17	<0.001	
WC (inch)	85.05±7.77	97.56±7.31	94.4±9.0	<0.001	
WHR	0.83±0.10	0.95±0.10	0.95±0.08	<0.001	
FPG (mmol/L)	5.14±0.40	6.26±0.17	9.69±2.41	<0.001	
Serum Insulin (μU/ml)	5.98±1.90	11.64±2.62	12.67±4.27	<0.001	
HOMA -IR.	0.78±0.25	1.60±0.31	1.89±0.64	<0.001	
Serum ferritin (ng/mL)	40.50±28.51	84.04±80.79	158.1±44.9	<0.001	
	Age	BMI	Serum Insulin (μU/ml)	HOMA -IR.	Serum ferritin (ng/mL)
Group A vs B	0.002	<0.001	<0.001	<0.001	<0.05
Group A vs C	<0.001	<0.001	<0.001	<0.001	<0.001
Group B vs C	<0.05	1.000	0.758	0.067	<0.001

Data were expressed as mean±SD; ANOVA test was performed to compare the three groups.

Table-II: Correlation of serum ferritin with BMI, FPG, serum insulin and HOMA IR

Name	Overall		Group A (NFG) (n=60)		Group B (IFG) (n=50)		Group C (T2DM) (n=30)	
Variables	r	p-value	r	p-value	r	p-value	r	p-value
BMI	0.297	0.007	0.384	0.515	0.185	0.376	0.383	0.159
FPG	0.520	<0.001	0.448	0.554	0.303	0.141	0.243	0.382
S.insulin	0.461	<0.001	0.191	0.238	0.156	0.456	0.129	0.648
HOMA -IR	0.504	<0.001	0.156	0.336	0.181	0.387	0.191	0.495

Correlation is significant at the 0.05 level (2-tailed); Pearson correlation coefficient test was performed.




Figure 1: Bar diagram showing mean ferritin concentration between three groups, showing increased serum ferritin levels in type 2 DM compared to the NFG and IFG groups.




Figure 2: Showing serum ferritin tertile with the association of glycemic status, where 86.7% of T2DM patients belonged to the highest tertile, which is statistically significant.

DISCUSSION

The impact of type 2 diabetes mellitus (T2DM) on Bangladesh's economic and social well-being is significant, with macrovascular complications appearing before the disease manifests. Screening for T2DM is crucial for surveillance and identifying individuals with prediabetes for timely interventions²⁵. Body iron stores are commonly assessed by serum ferritin, a key protein that regulates iron homeostasis, a widely available clinical biomarker to evaluate iron status¹². The study analyzed serum ferritin due to its interconnection with iron and glucose metabolism¹³. A total of 140 subjects were included in this study based on predefined enrollment criteria. The subjects comprised 60 normoglycaemic, 50 with impaired fasting glucose and 30 newly diagnosed type 2 diabetes mellitus. Therefore, this cross-sectional study evaluated the association between serum ferritin concentration and IR markers (fasting insulin, glucose and HOMA-IR) in Bangladeshi adult subjects of different glycemic states.

Serum ferritin levels were significantly higher in IFG and diabetics compared to the NFG group, consistent with previous research findings^{11,23}. In the present study, subjects with impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM) exhibited a notable rise in serum insulin and HOMA-IR levels when compared to the normal fasting glucose (NFG) group, as indicated in Table I. This finding aligns with the results reported by a previous study conducted over six years in France. The French study demonstrated that individuals with elevated serum ferritin levels faced an increased risk of hyperinsulinemia and high HOMA-IR values in both genders²⁶.

The exact mechanism linking elevated serum ferritin with insulin resistance IR is not fully understood, but several theories have been proposed. Iron's pro-oxidant nature can induce oxidative stress, disrupting insulin signaling at the cellular level¹³. Secondly, ferritin can increase pro-inflammatory cytokines, potentially mediating its association with IR²⁷. Thirdly, iron accumulation in the liver may interfere with insulin extraction, impairing glucose tolerance²⁷. Lastly, iron might hinder insulin action and glucose utilization in adipocytes, contributing

to IR. According to Pramiladevi et al.⁹ elevated serum ferritin levels might contribute to insulin resistance (IR) even before the onset of diabetes. A prospective study by Jung et al.²⁸ demonstrated that the risk of IR increased proportionately to serum ferritin levels, independent of metabolic factors, suggesting the predictive value of serum ferritin in IR. Frequent blood donation and phlebotomy therapy have been linked to improved insulin sensitivity, as reported in studies¹³. In this study, higher serum ferritin tertile levels were significantly associated with impaired glycemic states (IFG and T2DM) (Fig II), aligning with findings from a survey by Koo et al.²⁹, which suggested that hyperferritinemia might increase the risk of diabetes mellitus through heightened insulin resistance rather than dysfunctional beta cells. In a prospective study, Nakamura et al.³⁰ observed that clinically high-normal and mildly elevated iron storage in the body may cause diabetes, mainly by inducing insulin resistance, regardless of race. This influence is likely independent of the potential pathway between obesity and insulin resistance.

It was evident from the study that high serum ferritin, serum insulin and HOMA-IR were observed in IFG and type 2 diabetic subjects, and hyperferritinemia was significantly associated with insulin resistance markers like fasting insulin, glucose and HOMA-IR.

We found a positive association between ferritin and BMI and showed that higher serum ferritin is associated with increased BMI. However, we did not consider obesity status, which is positively correlated with the degree of insulin resistance.

CONCLUSION

To conclude, our data reveals a positive correlation between serum ferritin levels and glycemic status, particularly in IFG and diabetes mellitus type 2, compared to normoglycaemic subjects. IFG and type 2 diabetic subjects had higher insulin resistance markers (fasting insulin, glucose and HOMA-IR) levels than the NFG group, which presents significant opportunities in diagnosing and managing diabetes. This finding holds promise for predicting an individual's tendency to develop diabetes and related complications. Integrating serum ferritin assessments into screening programs could identify high-risk individuals, enabling targeted preventive measures. Lowering elevated serum ferritin levels through interventions offers a potential avenue for reducing

the morbidity and mortality associated with type 2 diabetes mellitus.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Brussels, Belgium: 2015.
2. World Health Organization (WHO). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva: WHO; 2006.
3. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A Balanced Overview. *Diabetes Care*. 1992;23:313-9.
4. Milner KL, Vander Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. *Gastroenterology*. 2010;138:932-41.
5. Dandona P, Hussain MA, Varghese Z, Politis D, Flynn DM, Hoffbrand AV. Insulin resistance and iron overload. *Ann Clin Biochem*. 1983;20:77-9.
6. Weinberg E.D. The hazards of iron loading. *Metallomics*. 2010;2:732-40.
7. Aregbesola A, Virtanen JK, Voutilainen S, Mursu J, Lagundoye A, Kauhanen J, Tuomainen TP. Serum ferritin and glucose homeostasis: Change in the association by glycaemic state. *Diabetes Metab Res Rev*. 2015;169:247-53.
8. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. *Biochim Biophys Acta*. 2009;1790(7):671-81.
9. Pramiladevi R, Boke U, Kora S. Serum ferritin levels in type II diabetes mellitus. *Sch J App Med Sci*. 2013;472-5.
10. Raj S, Rajan GV. Correlation between elevated serum ferritin and HbA1c in type 2 diabetes mellitus. *Int J Res Med Sci*. 2017;1(1):12-5.
11. Sharifi F, Sh. Sazandeh. Serum ferritin in type 2 diabetes mellitus and its relationship with HbA1c. *Acta Medica Iranica*. 2004;42(2):142-5.
12. Padwal MK. Association of serum ferritin levels with metabolic syndrome and insulin resistance. *J Clin Diagn Res*. 2015;9:11-3.
13. Fernandez-Real JM, Moreno A, Lopez-Bermejo B, Chico J, Vendrell W, Ricart W. Circulating soluble transferrin receptor according to glucose tolerance status and insulin sensitivity. *Diabetes Care*. 2007;30:604-8.
14. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest*. 2006;116(7):1793-801.
15. Chandrika N, Usha SM. Analysis of serum ferritin levels in nondiabetic, prediabetic, and diabetic individuals. *Int J Clin Biochem Res*. 2018;5:1-4.
16. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. *Diabetes Care*. 2004;27:2422-8.
17. Fumeron F, Vari IS, Grandchamp B, Balkau B. Association of serum ferritin and the development of metabolic syndrome in middle-aged Korean men: a 5-year follow-up study. *Diabetes Care*. 2012;29:2090-4.
18. Sheu WH, Chen YT, Lee WJ, Wang CW. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. *Clin Endocrinol*. 2003;58:380-5.
19. Suárez-Ortegón MF, Arbeláez A, Mosquera M, et al. Body iron stores as predictors of insulin resistance in apparently healthy urban Colombian men. *Biol Trace Elem Res*. 2012;145:283-5.
20. Fujimoto S, Kawakami N, Ohara A. Nonenzymatic glycation of transferrin: decrease of iron-binding capacity and increase of oxygen radical production. *Biol Pharm Bull*. 1995;18(3):396-400.
21. Bonfils L, Ellervik C, Friedrich N, Linneberg A, Sandholt CH, Jørgensen ME, et al. Fasting serum levels of ferritin are associated with impaired pancreatic beta cell function and decreased insulin sensitivity: a population-based study. *Diabetologia*. 2015;58(3):523-33.
22. Khondker F, Roy MN, Saha PR, Huq R, Ahmed R, Biswas S. Relationship Between Serum Ferritin Level and Hba1c in Bangladeshi Type 2 Diabetic Patients. *Anwer Khan Modern Med Coll J*. 2018;9(1):29-33.
23. Pham NM, Nanri A, Yi S, Kurotani K, Akter S, Foo LH, Mizoue T. Serum ferritin is associated with markers of insulin resistance in Japanese men but not in women. *Metabolism*. 2013;62:561-567.
24. Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. *Metabolism Clin Exp*. 2011;60:414-420.

25. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm. *Am J Med.* 2005;DOI:10.1016.05.018.
26. Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care.* 2007;30:1795-1801.
27. Ruddell RG, Hoang LD, Barwood JM, et al. Ferritin functions as a pro-inflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. *Hepatology.* 2009;49:887-900.
28. Jung CH, Lee MJ, Hwang JY, Jang JE, Leem J, Park JY, Lee WJ. Elevated serum ferritin level is associated with the incident type 2 diabetes in healthy Korean men: a 4-year longitudinal study. *PLoS One.* 2013.DOI:/10.1371/journal. pone. 0075250.
29. Koo BK, Yi SW, Moon MK. Serum ferritin level is an independent predictor of insulin resistance in non-diabetic men aged between 30-69 years: Korean National Health and Nutrition Examination Survey 2008-2010. *J Lipid Atheroscler.* 2013;2:69-76.
30. Nakamura K, Sakurai M, Morikawa Y, Nagasawa S, Miura K, Ishizaki M, et al. Serum ferritin, insulin resistance, and β -cell dysfunction: a prospective study in normoglycemic Japanese men. *Exp Clin Endocrinol Diabetes.* 2016;125:12-20.